JAK1 and graft versus host disease: Ruxolitinib, a JAK1/2 inhibitor, has been shown to ameliorate mouse and human GVHD and has been approved by the Food and Drug Administration (FDA) in the United States for the treatment of steroid-refractory acute GVHD (78, 79).